PMID- 32868644
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 31
IP  - 9
DP  - 2020 Oct
TI  - Lower response to trastuzumab emtansine in metastatic breast cancer patients with 
      human epidermal growth factor receptor 2 immunohistochemistry score of 2 and 
      fluorescence in situ hybridization positive compared with immunohistochemistry 
      score of 3: a retrospective study.
PG  - 973-978
LID - 10.1097/CAD.0000000000000939 [doi]
AB  - Tumor human epidermal growth factor receptor 2 (HER2) status is defined by either 
      protein expression using immunohistochemistry (IHC) or gene amplification using 
      fluorescence in situ hybridization (FISH). Approximately 20% of HER2-positive 
      breast cancer is HER2 IHC 2+/FISH-positive. Unlike trastuzumab, it has not been 
      studied whether the response to trastuzumab emtansine (T-DM1) differs according 
      to HER2-positive status. We retrospectively identified and reviewed medical 
      records of all patients with HER2-positive advanced breast cancer (ABC) who 
      received T-DM1 in our hospital from October 2013 to December 2016. We compared 
      the objective response rate (ORR) and progression-free survival (PFS) between 
      patients in the HER2 IHC 3+ group and those in the HER2 IHC 2+/FISH-positive 
      group. A total of 39 patients (IHC 3+: n = 32; IHC 2+/FISH-positive: n = 7) were 
      analyzed. Nineteen (48.7%), 13 (33.3%), and 29 (74.4%) patients had received at 
      least one prior chemotherapy, more than three lines of chemotherapy, and prior 
      pertuzumab for ABC, respectively. ORR was significantly higher in the IHC 3+ 
      group than in the IHC 2+/FISH-positive group (53.3% vs. 0%, P = 0.024). Median 
      PFS was 7.9 months in the IHC 3+ group versus 3.9 months in the IHC 
      2+/FISH-positive group (hazard ratio 0.68; 95% confidence interval 0.28-1.69, P = 
      0.408). Among the HER2-positive ABC patients treated with T-DM1, ORR was 
      significantly worse in HER2 IHC 2+/FISH-positive than in HER2 IHC 3+ patients. 
      Median PFS tended to be shorter in patients with HER2 IHC 2+/FISH-positive.
FAU - Yazaki, Shu
AU  - Yazaki S
AD  - Department of Internal Medicine, Division of Medical Oncology, St. Luke's 
      International Hospital.
FAU - Hashimoto, Jun
AU  - Hashimoto J
AD  - Department of Internal Medicine, Division of Medical Oncology, St. Luke's 
      International Hospital.
FAU - Ogita, Shin
AU  - Ogita S
AD  - Department of Internal Medicine, Division of Medical Oncology, St. Luke's 
      International Hospital.
FAU - Nakano, Eriko
AU  - Nakano E
AD  - Department of Internal Medicine, Division of Medical Oncology, St. Luke's 
      International Hospital.
FAU - Suzuki, Koyu
AU  - Suzuki K
AD  - Department of Pathology, St. Luke's International Hospital, Chuo-ku, Tokyo, 
      Japan.
FAU - Yamauchi, Teruo
AU  - Yamauchi T
AD  - Department of Internal Medicine, Division of Medical Oncology, St. Luke's 
      International Hospital.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - SE2KH7T06F (Ado-Trastuzumab Emtansine)
SB  - IM
MH  - Ado-Trastuzumab Emtansine/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Immunological/therapeutic use
MH  - Breast Neoplasms/*drug therapy/*enzymology/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Progression-Free Survival
MH  - Receptor, ErbB-2/*metabolism
MH  - Retrospective Studies
EDAT- 2020/09/02 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/09/02 06:00 [entrez]
AID - 00001813-202010000-00012 [pii]
AID - 10.1097/CAD.0000000000000939 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2020 Oct;31(9):973-978. doi: 10.1097/CAD.0000000000000939.